Workflow
LSPG(301111)
icon
Search documents
粤万年青(301111) - 2024年内部控制审计报告
2025-04-25 11:31
w 广东万年青制药股份有限公司 内部控制审计报告 华兴审字[2025]24014650051 号 华兴会计师事务所(特殊普通合伙) 内部控制审计报告 华兴审字[2025]24014650051 号 会计师事务所(特殊普通 IG CERTIFIED PUBLIC ACCOUN 地址:福建省福州市湖东路152号中山大厦B座6-9楼 Add : 6-9/F Block B,152 Hudong Road,Fuzhou,Fujian,China 广东万年青制药股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业标准的相关要求, 我们审计了广东万年青制药股份有限公司(以下简称粤万年青)2024 年 12 月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部 控制评价指引》的规定,建立健全和有效实施内部控制,并评价其有效性是 企业董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上,对财务报告内部控制的有效性 发表审计意见,并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 ...
粤万年青(301111) - 华兴会计师事务所(特殊普通合伙)关于广东万年青制药股份有限公司2024年非经营性资金占用及其他关联资金往来情况的专项审核说明
2025-04-25 11:31
w 关于广东万年青制药股份有限公司 2024 年非经营性资金占用及其他关联资金 往来情况的专项审核说明 华兴专字[2025]24014650045 号 华兴会计师事务所(特殊普通合伙) 关于广东万年青制药股份有限公司 2024 年非经营性资金占用及其他关联资金 往来情况的专项审核说明 华兴专字[2025]24014650045 号 广东万年青制药股份有限公司全体股东: 我们接受委托,审计了广东万年青制药股份有限公司(以下简称 "粤万年青"或"公司")财务报表,包括 2024 年 12 月 31 日的合并及 母公司资产负债表,2024 年度的合并及母公司利润表、合并及母公司现 金流量表、合并及母公司所有者权益变动表,以及财务报表附注,并 出具了"华兴审字[2025]24014650023 号"审计报告。 三、注册会计师的责任 我们的责任是对上述汇总表进行审核,并出具专项说明。 1 会计师事务所(特殊普通合 G CERTIFIED PUBLIC ACCOUNTAN 四、工作概述 我们将上述汇总表与粤万年青的有关会计资料进行了核对,在所有 重要方面未发现存在重大不一致的情形。除了在财务报表审计过程中对 粤万年青关联 ...
粤万年青(301111) - 华兴会计师事务所(特殊普通合伙)关于广东万年青制药股份有限公司2024年度募集资金存放与实际使用情况鉴证报告
2025-04-25 11:31
w 关于广东万年青制药股份有限公司 2024 年度募集资金存放与实际使用情况 鉴证报告 华兴专字[2025]24014650031 号 华兴会计师事务所(特殊普通合伙) 关于广东万年青制药股份有限公司 鉴证报告 华兴专字[2025]24014650031 号 广东万年青制药股份有限公司全体股东: 我们接受委托,审核了后附的广东万年青制药股份有限公司(以 下简称"粤万年青"或"公司")《关于 2024 年度募集资金存放与实 际使用情况的专项报告》(以下简称"专项报告")。 一、对报告使用者和报告目的的限定 本鉴证报告仅供粤万年青 2024 年度报告披露时使用,不得用作 任何其他目的。我们同意将本鉴证报告作为粤万年青 2024 年度报告 的必备文件,随其他文件一起报送并对外披露。 二、董事会的责任 2024 年度募集资金存放与实际使用情况 四、工作概述 我们按照《中国注册会计师其他鉴证业务准则第 3101 号 -- 历 史财务信息审计或审阅以外的鉴证业务》的规定执行了紧证业务。该 准则要求我们计划和实施鉴证工作,以对鉴证对象是否不存在重大错 报获取合理保证。在鉴证过程中,我们进行了审慎调查,实施了包括 检查会计记 ...
粤万年青(301111) - 民生证券股份有限公司关于广东万年青制药股份有限公司2024年度募集资金存放与实际使用情况的核查意见
2025-04-25 11:31
民生证券股份有限公司关于 广东万年青制药股份有限公司 2024 年度募集资金存放与实际使用情况的核查意见 民生证券股份有限公司(以下简称"民生证券"或"保荐机构")作为广东万年 青制药股份有限公司(以下简称"粤万年青"或"公司")首次公开发行股票并在创 业板上市的保荐机构,根据《证券发行上市保荐业务管理办法》《上市公司监管 指引第 2 号——上市公司募集资金管理和使用的监管要求》《深圳证券交易所创 业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板 上市公司规范运作》等有关规定,对粤万年青 2024 年度募集资金存放与实际使 用情况进行核查,核查情况及核查意见如下: 一、募集资金基本情况 (一)实际募集资金金额、资金到位时间 经深圳证券交易所创业板上市委 2021 年第 33 次审议会议审议通过和中国 证券监督管理委员会《关于同意广东万年青制药股份有限公司首次公开发行股票 注册的批复》(证监许可 [2021]3216 号)同意注册,公司首次向社会公开发行人 民币普通股(A 股)40,000,000.00 股,每股面值人民币 1.00 元,每股发行认购价 格为人民币 10.48 元,募集 ...
粤万年青(301111) - 2025 Q1 - 季度财报
2025-04-25 11:25
Financial Performance - The company's revenue for Q1 2025 was ¥70,812,585.48, a decrease of 0.54% compared to ¥71,196,522.47 in the same period last year[5] - The net profit attributable to shareholders was a loss of ¥3,441,732.40, representing a decline of 129.32% from a profit of ¥11,738,167.74 in the previous year[5] - The basic and diluted earnings per share were both -¥0.02, down 128.57% from ¥0.07 in the previous year[5] - The company reported a net profit attributable to shareholders of -3.44 million RMB, a decrease of 129.32% compared to the same period last year[17] - Operating revenue for the first quarter of 2025 was 70.81 million RMB, a slight decrease of 0.54% year-on-year[17] - The company reported a net profit of -4,103,207.13, compared to a net profit of 11,469,685.34 in the previous period, indicating a significant decline[25] - Operating profit was -3,285,979.26, down from 13,315,867.35 in the previous period, reflecting a substantial decrease in operational performance[25] - The company recorded a total profit of -3,224,388.91, compared to 13,523,137.86 in the previous period, indicating a significant drop in overall profitability[25] Cash Flow - The net cash flow from operating activities was -¥15,921,419.26, a significant decrease of 23,162.65% compared to -¥68,441.98 in the same period last year[5] - The net cash flow from operating activities was -15.92 million RMB, a significant decline of 23,162.65% due to ongoing investments in new business segments[13] - Cash flow from operating activities showed a net outflow of -15,921,419.26, compared to a much smaller outflow of -68,441.98 in the previous period[27] - The company's cash and cash equivalents decreased to CNY 104,933,304.35 from CNY 159,100,886.52[20] - Total cash and cash equivalents at the end of the period were 104,933,304.35, down from 159,100,886.52 at the beginning of the period[28] - The company’s cash flow from financing activities showed a net inflow of 3,780,503.08, compared to an outflow of -284,803.09 in the previous period[28] Assets and Liabilities - Total assets at the end of the reporting period were ¥920,505,782.32, a decrease of 1.36% from ¥933,166,569.41 at the end of the previous year[5] - The total assets of the company as of March 31, 2025, were CNY 920,505,782.32, down from CNY 933,166,569.41 at the beginning of the period[22] - The total liabilities decreased to CNY 154,394,324.06 from CNY 166,415,829.70[23] - The company's retained earnings decreased to CNY 159,732,407.59 from CNY 163,174,139.99[23] Investments and Acquisitions - The goodwill increased by 42.67% to ¥10,446,611.65 due to the acquisition of Hainan Wanmitang Pharmaceutical Co., Ltd.[11] - The company expanded its medical health business segment, leading to a 55.09% increase in other receivables to ¥4,169,836.54[11] - The company reported a 114.99% increase in trading financial assets to ¥74,847,626.64, primarily due to new financial products purchased during the period[9] - The company incurred non-recurring gains of ¥1,214,492.33 during the reporting period[7] - The acquisition of Hainan Wanmitang Pharmaceutical Co., Ltd. impacted profits by 11.06 million RMB, reflecting the costs associated with integrating new operations[17] - Hainan Wanmitang acquired 100% equity of Jiangxi Yuanqifud Pharmacy Chain Co., Ltd. and its 5 stores for CNY 500,000, enhancing its market presence through digital marketing strategies[19] - The company increased its investment in Noah Weikang by CNY 5.2 million, raising its ownership from 81% to 87.5%[19] Expenses - Management expenses increased by 61.07% to 12.67 million RMB due to the expansion into the healthcare and traditional Chinese medicine sectors[12] - Financial expenses rose by 154.43% to 0.24 million RMB, primarily due to increased financing costs from lease amortization[12] - Investment income decreased by 60.93% to 1.15 million RMB, attributed to reduced idle funds available for investment and lower financial market yields[12] - The company incurred a credit impairment loss of 135.42 thousand RMB, a decrease of 91.94% due to reduced bad debt write-offs[12] Sales and Market Performance - The company successfully won the national procurement for the product "Shengqi Jiangtang Pian," with a price reduction of approximately 30% compared to the original sales price, which is expected to expand sales in public hospitals and increase market share[18] - The registered capital of the subsidiary Hainan Wanmitang was increased from CNY 1 million to CNY 11 million, with the company holding a 51% stake post-increase[18] - The company received cash inflows from sales of 70,284,058.33, an increase from 67,764,781.90 in the previous period[27] Overall Financial Condition - The weighted average return on equity was -0.45%, down from 1.50% in the previous year[5] - The company's total comprehensive income attributable to the parent company was significantly lower, reflecting the overall decline in financial performance[26]
粤万年青(301111) - 2024 Q4 - 年度财报
2025-04-25 11:25
Financial Performance - The company's operating revenue for 2024 was ¥278,638,789.67, a decrease of 4.71% compared to ¥292,397,132.03 in 2023[18]. - The net profit attributable to shareholders for 2024 was ¥4,162,684.65, representing a significant decline of 87.57% from ¥33,501,697.88 in 2023[18]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥6,532,207.68 in 2024, a decrease of 127.65% compared to ¥23,623,155.29 in 2023[18]. - The cash flow from operating activities for 2024 was ¥3,208,543.56, a turnaround from -¥12,799,223.82 in 2023, marking an increase of 125.07%[18]. - The total assets at the end of 2024 were ¥933,166,569.41, reflecting a growth of 9.07% from ¥855,535,468.09 at the end of 2023[18]. - The basic earnings per share for 2024 were ¥0.03, down 85.71% from ¥0.21 in 2023[18]. - In 2024, the company achieved operating revenue of 27,863.88 million yuan, a decrease of 1,375.83 million yuan or 4.71% year-on-year[41]. - The net profit attributable to shareholders was 416.27 million yuan, down 2,933.90 million yuan or 87.57% year-on-year; the net profit after deducting non-recurring gains and losses was -653.22 million yuan, a decrease of 3,015.54 million yuan or 127.65% year-on-year[41]. Dividend Distribution - The company plans to distribute a cash dividend of 0.50 RMB per 10 shares to all shareholders, based on a total of 160,000,000 shares[6]. - The annual cash dividend proposal for 2024 is set at 0.5 yuan per 10 shares, totaling 8,000,000 yuan (including tax) for 160,000,000 shares[135]. - The company has maintained a stable profit distribution policy, ensuring reasonable returns to investors[132]. - There are no plans for stock dividends or capital reserve transfers in the current profit distribution proposal[135]. Business Strategy and Development - The company is focusing on the traditional Chinese medicine sector, leveraging its unique advantages in chronic disease prevention and health management[28]. - The company aims to enhance the quality and innovation of traditional Chinese medicine through new regulatory guidelines and digital transformation initiatives[30]. - The company is focusing on developing a health ecosystem covering prevention, diagnosis, and rehabilitation through three main business segments: traditional Chinese medicine, medical services, and health management[33]. - The company is actively pursuing new product development and market strategies through its various healthcare investments[74]. - The company is developing functional health foods based on the concept of "medicinal food homology," with a focus on high-end nourishing products sourced from Southeast Asia[93]. - The healthcare services segment will focus on a comprehensive life-cycle health management model, integrating prevention, diagnosis, rehabilitation, and health maintenance services[93]. Market and Industry Trends - The national strategy continues to promote the development of traditional Chinese medicine, aiming for a trillion-level health industry by 2030[28]. - The pharmaceutical industry in China achieved a revenue of CNY 29,762.7 billion, remaining flat year-on-year, while profits decreased by 0.9% to CNY 4,050.9 billion[29]. - The traditional Chinese medicine sector saw a decline in revenue and profit by 2.3% and 0.2% respectively[29]. - The company is positioned to benefit from policy incentives and market demand, driving the industry towards standardization and internationalization[28]. Risk Management - The management has highlighted potential risks and corresponding measures in the future development outlook section[5]. - The company faces risks in expanding its healthcare services due to the time required for market cultivation, which may impact short-term profitability[94]. - The company is exposed to risks related to the supply and price volatility of raw materials, particularly Chinese medicinal herbs, which could impact profitability[95]. - The company will strengthen research and analysis of the upstream Chinese medicinal materials market to effectively reduce risks related to raw material supply and price fluctuations[96]. Corporate Governance - The board of directors consists of 7 members, including 3 independent directors, ensuring compliance with legal and regulatory requirements[102]. - The company has a dedicated audit committee responsible for overseeing internal control systems and the authenticity of financial information[105]. - The company actively engages with investors through various platforms, ensuring transparency and protecting the rights of minority shareholders[103]. - The company has established a comprehensive internal control system to improve governance and operational efficiency[101]. - The company has committed to maintaining a high level of information disclosure, ensuring that all shareholders have equal access to company information[103]. Environmental Responsibility - The company holds a pollution discharge permit valid from August 25, 2023, to August 24, 2028, for various manufacturing activities[142]. - The company complies with the wastewater discharge standards, with CODcr levels at 89 mg/L, which is below the limit of 100 mg/L[143]. - The company has implemented measures to ensure that ammonia nitrogen levels in wastewater do not exceed the standard of 8 mg/L[143]. - The company has not reported any instances of exceeding pollution discharge limits during the reporting period[143]. - The company has invested CNY 523,500 in environmental governance and protection during the reporting period[146]. Employee Management - The company reported a total of 667 employees at the end of the reporting period, with 292 in the parent company and 375 in major subsidiaries[128]. - The employee composition includes 147 production staff, 224 sales personnel, 57 technical staff, 27 financial staff, and 212 administrative staff[128]. - The company has established a performance evaluation system linking employee salaries to company performance and key performance indicators[129]. - The company has conducted training programs focusing on new employee onboarding, GMP training, and management skills development[130]. Investment and Acquisitions - The company invested 680 million yuan to acquire 85% of Guangdong Tongren Pharmaceutical Co., Ltd., enhancing its capabilities in the Chinese herbal medicine and herbal pieces business[43]. - The company acquired 85% of Guangdong Wannianqing Pharmaceutical Co., Ltd. for 6.8 million yuan and has completed the business registration change[137]. - The company also acquired 51% of Hainan Wanmitang Pharmaceutical Co., Ltd. for 1.53 million yuan, but the business registration change has not yet been completed[137]. - The company has cumulatively used CNY 36,970.81 million of the raised funds, representing 84.02% of the total amount raised[81]. Shareholder Relations - The participation rate of investors in the 2024 first extraordinary general meeting was 56.18%[108]. - The participation rate of investors in the 2023 annual general meeting was 56.17%[109]. - The company has a total of 13,167 ordinary shareholders at the end of the reporting period, a decrease from 13,374 at the end of the previous month[200]. - The company has a total of 5 shareholders holding more than 5% of the shares, with the largest shareholder being Guangdong Jino Health Technology Co., Ltd.[200].
粤万年青(301111) - 关于使用部分闲置募集资金(含超募资金)和自有资金进行现金管理到期赎回并继续进行现金管理的公告
2025-04-15 07:42
证券代码:301111 证券简称:粤万年青 公告编号:2025-014 广东万年青制药股份有限公司 关于使用部分闲置募集资金(含超募资金)和自有资金进行 现金管理到期赎回并继续进行现金管理的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整,没有虚 假记载、误导性陈述或重大遗漏。 广东万年青制药股份有限公司(以下简称"公司")于 2024 年 12 月 18 日召 开第三届董事会第四次会议及第三届监事会第四次会议,并于 2025 年 1 月 3 日 召开 2025 年第一次临时股东大会,审议通过了《关于使用部分闲置募集资金 (含超募资金)和自有资金进行现金管理的议案》,同意公司在确保不影响正常 运营和募集资金投资项目建设的情况下,使用不超过人民币 2.5 亿元(含 2.5 亿 元)的闲置募集资金(含超募资金)及不超过人民币 2.5 亿元(含 2.5 亿元)的 自有资金进行现金管理,上述额度自股东大会审议通过之日起 12 个月内有效。 在上述额度和期限范围内,资金可循环滚动使用,并授权公司管理层在额度范 围内行使相关决策权、签署相关合同文件等。具体内容详见公司于 2024 年 12 月 19 日及 ...
粤万年青(301111) - 关于持股5%以上股东减持股份变动触及5%的整数倍及减持计划期限届满暨实施结果的公告
2025-04-08 13:30
广东万年青制药股份有限公司 关于持股5%以上股东减持股份变动触及5%的整数倍及减持 计划期限届满暨实施结果的公告 公司股东合和投资控股(广州)合伙企业(有限合伙)保证向本公司提供 的信息内容真实、准确、完整,没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 广东万年青制药股份有限公司(以下简称"公司")于 2024 年 12 月 16 日在 巨潮资讯网(www.cninfo.com.cn)披露了《关于持股 5%以上股东股份减持计划 的预披露公告》 (公告编号:2024-045),股东合和投资控股(广州)合伙企业 (有限合伙)(以下简称"合和投资")计划自该公告披露之日起十五个交易日 后的三个月内(2025 年 1 月 7 日-2025 年 4 月 6 日)以集中竞价、大宗交易方式 合计减持公司股份不超过4,800,000股,即减持比例不超过公司总股本的3.00%。 公司于 2025 年 3 月 24 日在巨潮资讯网(www.cninfo.com.cn)披露了《关于 持股 5%以上股东减持股份暨权益变动触及 1%的公告》,合和投资通过集中竞价及 大宗交易 ...
粤万年青(301111) - 简式权益变动报告书(合和投资)
2025-04-08 13:30
广东万年青制药股份有限公司 简式权益变动报告书 上市公司名称:广东万年青制药股份有限公司 上市地点:深圳证券交易所 股票简称:粤万年青 股票代码:301111 信息披露义务人:合和投资控股(广州)合伙企业(有限合伙) 住所/通讯地址:广州市天河区华强路 3 号之二 2602 房(自编:B7) 股权变动性质:持股比例减少 签署日期:2025 年 4 月 8 日 一、本报告书系信息披露义务人依据《公司法》《证券法》《上市公司收购 管理办法》《证券期货法律适用意见第 19 号—<上市公司收购管理办法>第十三 条、第十四条的适用意见》和《公开发行证券的公司信息披露内容与格式准则第 15 号-权益变动报告书》等相关法律、法规及规范性文件编制。 二、信息披露义务人签署本报告书已获得必要的授权和批准,其履行不违反 信息披露义务人章程或内部规则中的任何条款,或与之相冲突。 三、依据《证券法》《上市公司收购管理办法》《公开发行证券的公司信息 披露内容与格式准则第 15 号-权益变动报告书》相关规定,本报告书已全面披露 了信息披露义务人在粤万年青拥有权益的股份变动情况。 截至本报告书签署日,除本报告书披露的信息外,信息披露义务人 ...
粤万年青(301111) - 关于持股5%以上股东减持股份暨权益变动触及1%的公告
2025-03-24 09:14
证券代码:301111 证券简称:粤万年青 公告编号:2025-012 关于持股5%以上股东减持股份暨权益变动触及1%的公告 公司股东合和投资控股(广州)合伙企业(有限合伙)保证向本公司提供 的信息内容真实、准确、完整,没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 广东万年青制药股份有限公司(以下简称"公司")于 2024 年 12 月 16 日在 巨潮资讯网(www.cninfo.com.cn)披露了《关于持股 5%以上股东股份减持计划 的预披露公告》 (公告编号:2024-045),股东合和投资控股(广州)合伙企业 (有限合伙)(以下简称"合和投资"),计划自该公告披露之日起十五个交易 日后的三个月内(2025 年 1 月 7 日-2025 年 4 月 6 日),以集中竞价、大宗交易 方式合计减持公司股份不超过 4,800,000 股,即减持比例不超过公司总股本的 3.00%。 公司于近日收到合和投资的《关于减持股份触及 1%的告知函》,获悉合和投 资通过集中竞价及大宗交易的方式累计减持公司股份 1,698,000 股,占公司总股 本的比例为 ...